Drug Approval | March 01, 2022
USFDA approves CITI Biopharma’s Vonjo
Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients
Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients
The products are based on a combination of mushrooms and cannabinoids that have achieved a strong therapeutic effect using low concentrations of THC. The treatment is expected to be launched in Israel, US and UK in H2 2022
The company claims that this is the first time a mental wellness start-up has gone phygital in a Tier 2 city
Study to evaluate effectiveness of hypoglossal nerve stimulation
Confirmed positive phase 3 topline results in addition to Enavogliflozin monotherapy and Metformin combination therapy
N Yuvraj, Joint Secretary, Dept of Pharmaceuticals, Satish Reddy, Chairman, Dr Reddy’s Laboratories; Kiran Mazumdar Shaw, Executive Chairperson, Biocon Group; Sanjiv Navangul, MD & CEO, Bharat Serums and Vaccines and Shravil Patel, MD, Zydus Lifesciences discuss the way forward for the India pharma industry
The facility is spread across 215000 sq. feet and provides super-speciality care
The dedicated HPB and liver transplant centre will be headed by Dr. Vivek Vij, Chairman -Advanced Surgical GI, HPB & Liver Transplant and his team of experts
The new wing will cater to all aspects of mother and child health by offering comprehensive, end to end services in radiology, diagnostics, obstetric surgeries and an exclusive gynaecology emergency section
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
Subscribe To Our Newsletter & Stay Updated
